Progressive Changes in Cerebral Apparent Diffusion Values in Fabry Disease: A 5-Year Follow-up MRI Study

Koen P.A. Baas; Albert J. Everard; Simon Körver; Laura van Dussen; Bram F. Coolen; Gustav J. Strijkers; Carla E.M. Hollak; Aart J. Nederveen

doi:10.3174/ajnr.A8001

Abstract

BACKGROUND AND PURPOSE: White matter lesions are commonly found in patients with Fabry disease. Existing studies have shown elevated diffusivity in healthy-appearing brain regions that are commonly associated with white matter lesions, suggesting that DWI could help detect white matter lesions at an earlier stage This study explores whether diffusivity changes precede white matter lesion formation in a cohort of patients with Fabry disease undergoing yearly MR imaging examinations during a 5-year period.

MATERIALS AND METHODS: T1-weighted anatomic, FLAIR, and DWI scans of 48 patients with Fabry disease (23 women; median age, 44 years; range, 15–69 years) were retrospectively included. White matter lesions and tissue probability maps were segmented and, together with ADC maps, were transformed into standard space. ADC values were determined within lesions before and after detection on FLAIR images and compared with normal-appearing white matter ADC. By means of linear mixed-effects modeling, changes in ADC and ΔADC (relative to normal-appearing white matter) across time were investigated.

RESULTS: ADC was significantly higher within white matter lesions compared with normal-appearing white matter (P < .01), even before detection on FLAIR images. ADC and ΔADC were significantly affected by sex, showing higher values in men (60.1 [95% CI, 23.8–96.3] ×10^–6mm²/s and 35.1 [95% CI, 6.0–64.2] ×10^–6mm²/s), respectively. ΔADC increased faster in men compared with women (0.99 [95% CI, 0.27–1.71] ×10^–6mm²/s/month). ΔADC increased with time even when only considering data from before detection (0.57 [95% CI, 0.01–1.14] ×10^–6mm²/s/month).

CONCLUSIONS: Our results indicate that in Fabry disease, changes in diffusion precede the formation of white matter lesions and that microstructural changes progress faster in men compared with women. These findings suggest that DWI may be of predictive value for white matter lesion formation in Fabry disease.

ABBREVIATIONS:

ERT: enzyme replacement therapy
IQR: interquartile range
LME: linear mixed effect
MNI: Montreal Neurological Institute
NAWM: normal-appearing white matter
TP: time point
WML: white matter lesion

Fabry disease is a rare, X-linked lysosomal storage disorder caused by a mutation in the galactosidase alpha (GLA) gene.¹ This mutation causes a deficiency of α-galactosidase A activity, resulting in the accumulation of glycosphingolipids, mainly globotriaosylceramide, primarily in the cardiovascular system, brain, and kidneys.² Accumulation in the arterial walls is believed to contribute to cerebrovascular and cardiac diseases, which are among the leading causes of death in patients with Fabry disease. Among other neurologic findings, white matter lesions (WMLs) are found in nearly one-half of all patients.^3⇓-5 WML burden increases with age and is associated with cognitive decline.^5,6 Although the prevalence, severity, and progression of WMLs are comparable in men and women, men develop WMLs at a younger age.^4,7 Moreover, a higher prevalence of WMLs in men with classic compared with nonclassic Fabry disease has been reported.⁸

The pathophysiology of WMLs in Fabry disease is complex and incompletely understood. Cell damage in the cerebrovascular system may impair the autoregulation of cerebral perfusion, resulting in a hyperdynamic circulation and endothelial dysfunction caused by shear stress and incompliant vessel walls.^4,9,10 Combined with glycosphingolipid storage in endothelial cells, these effects might cause the release of reactive oxygen species, further compromising endothelial cells and accelerating vascular dysfunction.^11,12 Patients with Fabry disease with and without WMLs have shown increased CBF but decreased glucose metabolism in the WM, indicating microangiopathy.¹³ Last, increased CSF protein levels have been reported, indicating blood-brain barrier dysfunction.¹⁴

MR imaging is the criterion standard imaging technique to detect brain alterations in Fabry disease, including WMLs. DWI can accurately quantify microstructural WM changes and has been used in patients with Fabry disease.^5,15,16 These studies showed elevated mean diffusivity in healthy-appearing brain regions that are commonly associated with WMLs.^5,15,16 Moreover, WM mean diffusivity was found to be correlated with plasma globotriaosylceramide levels.⁵ These findings suggest that DWI could help to detect WML formation at an earlier stage and potentially provide a tool to evaluate treatment options like enzyme replacement therapy (ERT). However, these studies were of a cross-sectional design, prohibiting the assessment of longitudinal changes required to investigate whether changes in diffusion precede WML formation. Therefore, this study aimed to explore whether DWI can detect microstructural changes before WMLs appear on FLAIR-weighted images in a cohort of patients with Fabry disease undergoing yearly MR imaging examinations during a 5-year period.

MATERIALS AND METHODS

For this retrospective, observational study, we adhered to the guidelines of the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. Data collection has been described before.¹⁷ The Amsterdam University Medical Centers (location in the Academic Medical Center) are the national referral center for patients with Fabry disease in the Netherlands. Follow-up at the outpatient clinic ranged from 6 months to once every 2 years and included brain MR imaging scans. Follow-up data from patients with a confirmed Fabry disease diagnosis were collected in a local database after patients provided written informed consent. From this database, follow-up data collected between 2013 and 2019 were extracted. All patients were classified as having the classic or nonclassic phenotype using predefined criteria.^8,18,19 Patients were included if good-quality FLAIR-weighted, T1-weighted, and DWI scans from at least 3 visits were available. According to Dutch law, no approval of the study protocol was needed because this was a retrospective study and patients were not subjected to procedures or rules of behavior in addition to regular clinical follow-up.

Image Acquisition

MR imaging scans were acquired on 3T scanners (Ingenia; Philips Healthcare). T1-weighted anatomic scans were acquired with the following parameters: TR/TE: 9/4.1 ms, flip angle: 8°, resolution: 0.5 × 0.5 × 0.9 mm³, FOV: 256 × 256 × 170 mm³, and number of averages: 1. DWI scans were acquired with 2 b-values, 0 and 1000 s/mm². Other acquisition parameters were the following: TR/TE: 6340/83 ms, flip angle: 90°, resolution: 0.9 × 0.9 × 3.0 mm³, FOV: 229 × 229 ×147 mm³, and number of averages: 2. FLAIR acquisition parameters were as follows: TR/TE: 4800/356 ms, flip angle: 90°, resolution: 1.04 × 1.04 × 1.12 mm³, FOV: 250 × 250 × 360 mm³, and number of averages: 2. MR imaging software upgrades introduced some variation in acquisition parameters of the DWI scan (Online Supplemental Data). Periodic image-quality tests using a vendor-provided phantom were performed during the course of the study, including before and after software upgrades. Any observed abnormalities were addressed by the vendor before continuation. Patient positioning and planning of the scans were performed according to standard clinical procedures. FLAIR scans were assessed by a neuroradiologist for WMLs according to the Fazekas scale. The Fazekas scale rates WMLs in the periventricular and deep brain separately from zero (no WMLs) to 3 (severe confluent WMLs) and adds both scores, resulting in a total score that can range from zero to 6.

Postprocessing

Postprocessing was performed in Matlab (Version 2019b; MathWorks). An overview of the processing steps is schematically shown in Fig 1.

FIG 1.

Overview of postprocessing steps. T1-weighted scans were segmented in native space and registered to MNI space (A). WMLs were automatically segmented on FLAIR images, thresholded, and manually corrected (B). ADC maps were fitted from DWIs with b-value = 0 and 1000 s/mm² (C). WML masks and ADC maps were registered to MNI space using the transformation matrix from the T1 registration. NAWM masks were created by subtracting the WML masks from the WM segmentation (D). WML masks were eroded with 2 voxels. Last, GM and CSF masks were dilated with 3 voxels and subtracted from the resulting WML mask and NAWM mask.

T1-weighted scans were segmented into GM, WM, and CSF probability maps using CAT12 (https://neuro-jena.github.io/cat12-help/) and nonlinearly registered to standard Montreal Neurological Institute (MNI) space using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12) (Fig 1A). After registration to MNI space, tissue probability maps were thresholded at 0.8.

WMLs were automatically segmented on the FLAIR images using the lesion segmentation toolbox (https://www.applied-statistics.de/lst.html) lesion-prediction algorithm²⁰ and manually corrected (Fig 1B). This segmentation was performed only on FLAIR images that were scored >0 on the Fazekas score to avoid false-positive detections. WML probability maps were thresholded at 0.2, which was deemed appropriate on the basis of visual inspection (Online Supplemental Data). Corrected WML maps were registered to MNI space.

ADC maps were fitted from the DWI data using the FMRIB Software Library (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) (Fig 1C) and registered to MNI space using the previously obtained transformation matrix.

After transformation to MNI space, normal-appearing white matter (NAWM) was defined by subtracting the WML masks of every available time point (TP) from the WM masks (Fig 1D). WML and NAWM masks were eroded by 1 voxel, and 3-voxel dilated GM and CSF masks were subtracted from the resulting masks to prevent partial volume effects. Unconnected lesions of <5 voxels were excluded (not shown). The resulting lesion masks were termed “full lesion.” Additionally, masks were created that included only WMLs that developed between 2 study visits, denoted as “new lesion.” New lesion masks were created by subtracting the single-voxel dilated full lesion masks from all previous TPs from the current full lesion mask. Again, lesions of <5 voxels were excluded.

The median ADC within the created masks was calculated at each TP (before and after the first appearance on FLAIR-weighted images; Online Supplemental Data). Naming conventions as in the Online Supplemental Data will be used. The TP of first detection on a FLAIR-weighted image was defined the reference TP (time = 0) for that ROI, to which all ADC values were temporally shifted. The difference between ADC within WMLs and NAWM (ΔADC) was calculated by subtracting the median ADC within the NAWM from the lesion ADC.

Statistical Analysis

Statistical analyses were performed in R Studio (Version 2022.2.3.492; http://rstudio.org/download/desktop). Descriptive statistics are reported as mean (SD) or median and interquartile range (IQR) if not normally distributed. ADC values within full and new lesions were compared with corresponding NAWM ADC values using 2-tailed paired t tests with a Bonferroni multiple comparison correction.

Linear mixed effect (LME) modeling was used to investigate changes in ADC and ΔADC with time.²¹ This investigation was only for new lesions because the age of lesions originating from before the first MR imaging scan was unknown. Subjects were assigned as the random effect and TP of lesion segmentation as a crossed random effect to account for multiple TPs per patient and multiple lesion segmentations per patient, respectively.²² The random effects structure was determined for each model separately as described in the Online Supplemental Data. Next, a priori–determined fixed and interaction effects were added. Fixed effects included time (in months, respectively, to the reference point), sex, and age. Age at baseline was used and centered around the mean. Finally, interaction effects between time and sex and between time and age were included.

If the model could not converge, the structure was simplified as described in the Online Supplemental Data. Model assumptions were tested by fitting of the residuals against the observed data and inspecting their normality. Estimated effects and their 95% CIs are reported.

Models were also evaluated using only the ADC values before detection on FLAIR-weighted images (time < 0). To investigate NAWM ADC in patients with and without lesions, we included a grouping variable “presence of lesions” as a fixed effect, indicating whether WMLs, at any TP, had been found in a patient.

Data Availability

Data are available on reasonable request but not publicly available. Because of the rarity of the disease, even anonymized data can be linked to a specific individual.

RESULTS

Data from 49 patients with Fabry disease initially fulfilled the inclusion criteria. Five FLAIR scans and three T1 scans were excluded because of artifacts detected during image analysis, leading to the exclusion of 1 patient because <3 complete TPs were available. After exclusion, 48 patients with Fabry disease (23 women, all classic phenotypes, all on ERT) with a median of 5 TPs (range, 3–6 TPs) were left, totaling 229 included scan data sets (Table 1). The median interval between TPs was 364 days (range, 196–1134 days). At baseline, 29 (60%) patients had WMLs (18 women; median age, 49 years; range, 21–69 years). Four patients without WMLs at baseline developed WMLs during the study, totaling 33 (69%) patients (18 women; median age, 47 years; range, 21–69 years) who had WMLs by the end of the study. In patients who had lesions at baseline, lesion volume increased significantly during the study (median, 0.6 [IQR, 1.6] mm³ and 1.05 [IQR, 3.1] mm³; Z = 15, P < .01).

View this table:

Table 1:

Patient characteristics and WML scores

WMLs were predominantly found in the periventricular WM (Fig 2). At time point 1 (TP1), the mean ADC within NAWM was 765 (SD, 32) × 10⁻⁶ mm²/s compared with 1113 (SD, 138) × 10⁻⁶ mm²/s (t[24] = −14, P < .01) within the full lesion at that TP (full lesion TP1). ADC within full lesion ROIs from all TPs are shown in the Online Supplemental Data.

FIG 2.

Lesion prevalence in patients with Fabry disease. Y, Z, and X coordinates refer to standard MNI space.

When we combined new lesion ADC values with the same time respective to their reference point, ADC was significantly higher compared with NAWM up to 5 years before detection on FLAIR-weighted images (Fig 3A; t[8] = 3.9, P = .047). Similarly, ΔADC was significantly higher than zero up to 5 years before detection (Fig 3B; t(8) = 3.9, P = .047). Increased ADC values within WMLs before detection on FLAIR-weighted images also seemed apparent on FLAIR scans and ADC maps of individual patients who developed new WMLs during the study (Fig 4).

FIG 3.

ADC (A) and ΔADC (B) in new lesion ROIs compared with NAWM. ADC within lesions with the same time (in years) relative to their reference point were combined to calculate mean values (data points) and their SDs (shaded areas). For example, ADC_TP1 within the new lesion TP2 and ADC_TP2 within new lesion TP3 both have time = −1 but are compared with the HAWM ADC from TP1 and TP2, respectively. Paired t tests showed that the ADC within lesions was significantly higher than the ADC within NAWM and that ΔADC was significantly higher than zero at every time. NAWM indicates normal appearing white matter.

FIG 4.

Yearly FLAIR scans and ADC maps. Three of these patients developed WMLs during the study (A–C), while 1 patient did not (D). Scans are shown in chronologic order from left to right. New WMLs are indicated by the orange arrows. The patient in B also had a large WM hyperintensity at the right parieto-occipital sulcus, which was diagnosed as a result of infarction before the study. Color scales are optimized for each patient individually. Z values indicate the Z coordinate in standard MNI space.

LME modeling revealed that sex had a small-but-significant positive fixed effect on NAWM ADC values, showing a 22.1 (95% CI, 3.7–40.4) ×10⁻⁶ mm²/s higher ADC intercept for men compared with women (P = .02; Online Supplemental Data). Neither time, age, nor the presence of lesions had a significant effect on NAWM ADC.

ADC and ΔADC within new lesions were significantly affected by sex, with higher intercepts in men compared with women (60.1 [95% CI, 23.8–96.3] ×10^–6 mm²/s, P < .01 and 35.1 [95% CI, 6.0–64.2] ×10^–6 mm²/s, P = .02 respectively; Tables 2 and 3). ADC but not ΔADC was also higher and increased faster in older patients, indicated by the fixed effect of age (2.1 [95% CI, 0.6–3.7] ×10^–6 mm²/s/month, P < .01) and the interaction effect between age and time (0.04 [95% CI, 0.00–0.07] ×10^–6 mm²/s/year/month, P = .03). The effects of time, sex, and age on ADC are shown in Fig 5. ΔADC values increased significantly faster in men compared with women (0.99 [95% CI, 0.27–1.71] ×10^–6 mm²/month, P < .01). Time itself had a significant fixed effect only on ΔADC (0.49 [95% CI, 0.03–0.95] ×10^–6 mm²/month, P = .04; Online Supplemental Data).

FIG 5.

Visualization of LME models describing the ADC within new lesions. The graphs show how time and sex would affect the ADC of 36-, 46-, and 56-year-old patients superimposed on the measured data (A–C respectively). ADC is higher and increases faster in men compared with women and increases faster in older patients.

View this table:

Table 2:

Summary of the obtained LME models describing ADC and ΔADC

View this table:

Table 3:

Summary of the obtained LME models describing ADC and ΔADC before lesion detection on FLAIR-weighted images

When we evaluated the models using only the TPs before detection, none of the effects describing ADC remained significant, though sex nearly did (35 [95% CI, –3.6–74.5] ×10^–6 mm², P = .075; Tables 2 and 3). For ΔADC, only the significant fixed effect of time remained (0.57 [95% CI, 0.01–1.14] ×10^–6 mm²/month, P = .047; Online Supplemental Data).

DISCUSSION

In this 5-year follow-up study, ADC within WMLs of patients with Fabry disease was assessed before and after detection on FLAIR-weighted images in a unique longitudinal data set. ADC values were already increased compared with NAWM in regions that at later TPs were positively identified as WMLs on FLAIR MR imaging. This increase in ADC with time was affected by sex, with men showing a faster increase in ADC than women.

With Fabry disease being an X-linked disease, men are generally more severely affected by it than women. Indeed, this study shows that ADC within WMLs is higher and diverges faster from NAWM values in men compared with women, a finding not observed before.^7,23,24 However, 1 study reported a comparable WML load between men and women, despite the men being younger, suggesting an earlier onset of WMLs in men.⁷ A different study comparing diffusivity was limited by its small sample size (n = 27), cross-sectional setup, and combined inclusion of classic and nonclassic patients.²⁴ Although here only slightly more patients with WMLs were included (n = 33), the longitudinal design resulted in 472 observations for the analysis.

Higher ADC values were found in regions confirmed as WML at later TPs, consistent with earlier research showing increased diffusivity in NAWM areas commonly associated with WMLs¹⁶ and indicating that changes in diffusion precede WML detection on FLAIR images. When only the TPs before detection were entered into the model, no effects remained statistically significant for ADC. For ΔADC, only time remained statistically significant. This finding may be explained by a lack of statistical power to detect changes in ADC while still detecting ADC increasing faster compared with NAWM. We did not develop a prediction model for WMLs based on ADC but merely showed an association between increased ADC and WML development at later TPs. To determine the predictive value of DWI, a model should be verified using a separate data set. Nevertheless, our findings add to the existing evidence that changes in diffusion precede the formation of WMLs in patients with Fabry disease.

The increasing ADC values with age in WMLs were not observed when considered relative to NAWM (ΔADC). This finding suggests that the observed effect of age is not WML-specific but rather affects WM globally. However, time had no significant effect on NAWM ADC. These ambiguous results emphasize the need for caution when interpreting the NAWM ADC results from this patient population. On the other hand, heterogeneous age-related microstructural alterations across the WM²⁵ might prevent the observation of a time effect when considering global WM ADC.

A limitation of this study is the absence of an age- and sex-matched control group. Therefore, ADC within lesions could be compared only with NAWM ADC from other brain regions. NAWM ADC values were similar to literature values from healthy control studies (804 [SD, 110] × 10⁻⁶ mm²/s).²⁶ However, it is possible that WM is affected globally in patients with Fabry disease and that areas detected as lesions are just more severely affected than NAWM. This possibility would align with the pathogenesis of patients with MS as observed in studies using magnetization transfer imaging²⁷ and DTI.²⁸ A potential continuation of this study could address this limitation by including a carefully matched healthy control group. Nonetheless, the assessment of diffusion within WMLs both before and after their detection on FLAIR images remained unaffected by the absence of a control group.

All patients included here received ERT, hampering the analysis of the effect of ERT. Treatment duration was explored as a parameter in the LME models but did not yield a statistically significant finding, possibly due to selection bias. Earlier studies reported ambiguous results on the effect of ERT on WMLs. Two studies did not find an effect,^3,29 while a third study found that WML burden was more likely to remain stable in patients on ERT.³⁰ Although its ability to evaluate ERT is uncertain, this study shows that DWI could still be useful in clinical decision-making. For example, ERT may be delayed until signs of disease progression are observed. In such cases, DWI could serve as a more sensitive marker for detecting early changes. Moreover, if DWI reveals that WMLs continue to progress despite ERT, this finding may be a signal to consider discontinuing the therapy. However, a more thorough validation of the predictive value of DWI must be performed before it can be relied on for such applications.

Some other limitations should be acknowledged. Due to the rarity of the disease, the number of included patients is relatively low, limiting statistical power. However, the longitudinal study design partly overcomes this limitation. Given the low sample size, exclusive inclusion of patients with the classic phenotype, and the primary focus on investigating the potential predictive value of DWI, a comparison among patients with different GLA gene mutations or phenotypes was not conducted, which remains a topic for future research. Second, because of the large number of MR images, a semiautomated approach was used to segment the WMLs rather than manual segmentation by a trained neuroradiologist. Last, the acquisition protocol used in this study was not initially designed for a scientific investigation but rather for initial exploration, explaining why a more comprehensive technique like DTI was not used in this patient group.

CONCLUSIONS

This work presents the analysis of a unique, longitudinal data set of DWI and FLAIR MR imaging in patients with Fabry disease. Adding to the existing body of literature, these results indicate that changes in diffusion precede the formation of WMLs, suggesting that DWI may be of predictive value for WML formation in Fabry disease. Moreover, these results show that WML diffusivity progresses faster in men compared with women.

Acknowledgment

ChatGPT (https://openai.com/chatgpt) has been used to improve the clarity, grammar, and overall quality of the manuscript.

Footnotes

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

References

1.↵
1. Fabry H
. Angiokeratoma corporis diffusum: Fabry disease—historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr 2002;91:3–5 doi:10.1111/j.1651-2227.2002.tb03102.x pmid:12572835
CrossRef PubMed
2.↵
1. Zarate YA,
2. Hopkin RJ
. Fabry’s disease. Lancet 2008;372:1427–35 doi:10.1016/S0140-6736(08)61589-5 pmid:18940466
CrossRef PubMed
3.↵
1. Jardim LB,
2. Aesse F,
3. Vedolin LM, et al
. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr .2006;64:711–17 doi:10.1590/s0004-282x2006000500002
CrossRef PubMed
4.↵
1. Körver S,
2. Vergouwe M,
3. Hollak CEM, et al
. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Mol Genet Metab 2018;125:205–16 doi:10.1016/j.ymgme.2018.08.014
CrossRef PubMed
5.↵
1. Ulivi L,
2. Kanber B,
3. Prados F, et al
. White matter integrity correlates with cognition and disease severity in Fabry disease. Brain 2020;143:3331–42 doi:10.1093/brain/awaa282 pmid:33141169
CrossRef PubMed
6.↵
1. Murphy P,
2. Williams F,
3. Davagnanam I, et al
. Cognitive dysfunction and white matter hyperintensities in Fabry disease. J Inherit Metab Dis 2022;45:782–95 doi:10.1002/jimd.12472 pmid:34994980
CrossRef PubMed
7.↵
1. Rost NS,
2. Cloonan L,
3. Kanakis AS, et al
. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology 2016;86:1880–86 doi:10.1212/WNL.0000000000002673 pmid:27164662
Abstract/FREE Full Text
8.↵
1. Arends M,
2. Wanner C,
3. Hughes D, et al
. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 2017;28:1631–41 doi:10.1681/ASN.2016090964 pmid:27979989
Abstract/FREE Full Text
9.↵
1. Fellgiebel A,
2. Keller I,
3. Marin D, et al
. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009;72:63–68 doi:10.1212/01.wnl.0000338566.54190.8a pmid:19122032
Abstract/FREE Full Text
10.↵
1. Rombach SM,
2. Twickler TB,
3. Aerts JM, et al
. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 2010;99:99–108 doi:10.1016/j.ymgme.2009.10.004 pmid:19900828
CrossRef PubMed
11.↵
1. Wei EP,
2. Kontos HA,
3. Beckman JS
. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol 1996;271(3 Pt 2):H1262–66 doi:10.1152/ajpheart.1996.271.3.H1262 pmid:8853367
CrossRef PubMed
12.↵
1. Moore DF,
2. Kaneski CR,
3. Askari H, et al
. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258–63 doi:10.1016/j.jns.2007.01.053 pmid:17362993
CrossRef PubMed
13.↵
1. Moore DF,
2. Altarescu G,
3. Barker WC, et al
. White matter lesions in Fabry disease occur in “prior” selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003;62:231–40 doi:10.1016/j.brainresbull.2003.09.021 pmid:14698356
CrossRef PubMed
14.↵
1. Böttcher T,
2. Rolfs A,
3. Tanislav C, et al
. Fabry disease: underestimated in the differential diagnosis of multiple sclerosis? PLoS One 2013;8:e71894 doi:10.1371/journal.pone.0071894 pmid:24015197
CrossRef PubMed
15.↵
1. Albrecht J,
2. Dellani PR,
3. Müller MJ, et al
. Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 2007;78:964–69 doi:10.1136/jnnp.2006.112987 pmid:17449543
Abstract/FREE Full Text
16.↵
1. Paavilainen T,
2. Lepomäki V,
3. Saunavaara J, et al
. Diffusion tensor imaging and brain volumetry in Fabry disease patients. Neuroradiology 2013;55:551–58 doi:10.1007/s00234-012-1131-8 pmid:23292181
CrossRef PubMed
17.↵
1. Körver S,
2. Longo MG,
3. Lima MR, et al
. Determinants of cerebral radiological progression in Fabry disease. J Neurol Neurosurg Psychiatry 2020;91:756–63 doi:10.1136/jnnp-2019-322268 pmid:32317398
Abstract/FREE Full Text
18.↵
1. Tol van der L,
2. Cassiman D,
3. Houge G, et al
. Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep 2014;17:83–90 doi:10.1007/8904_2014_342 pmid:25224312
CrossRef PubMed
19.↵
1. Smid BE,
2. Van Der Tol L,
3. Cecchi F, et al
. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol 2014;177:400–08 doi:10.1016/j.ijcard.2014.09.001 pmid:25442977
CrossRef PubMed
20.↵
1. Schmidt P
. Bayesian Inference for Structured Additive Regression Models for Large-Scale Problems with Applications to Medical Imaging. Mathematics January 17, 2017. https://www.semanticscholar.org/paper/Bayesian-inference-for-structured-additive-models-Schmidt/edc315de56ff336b75f36b30bad74fab231d39ca. Accessed June 20, 2022
21.↵
1. Bates D,
2. Mächler M,
3. Bolker BM, et al
. Fitting linear mixed-effects models using lme4. Journal of Statistical Software 2015;67 doi:10.18637/jss.v067.i01
CrossRef PubMed
22.↵
1. Baayen RH,
2. Davidson DJ,
3. Bates DM
. Mixed-effects modeling with crossed random effects for subjects and items. Journal of Memory and Language 2008;59:390–412 doi:10.1016/j.jml.2007.12.005
CrossRef PubMed
23.↵
1. Fellgiebel A,
2. Müller MJ,
3. Mazanek M, et al
. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005;65:600–02 doi:10.1212/01.wnl.0000173030.70057.eb pmid:16116124
Abstract/FREE Full Text
24.↵
1. Fellgiebel A,
2. Mazanek M,
3. Whybra C, et al
. Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. J Neurol 2006;253:780–87 doi:10.1007/s00415-006-0118-y pmid:16511647
CrossRef PubMed
25.↵
1. Burzynska AZ,
2. Preuschhof C,
3. Bäckman L, et al
. Age-related differences in white matter microstructure: region-specific patterns of diffusivity. Neuroimage 2010;49:2104–12 doi:10.1016/j.neuroimage.2009.09.041 pmid:19782758
CrossRef PubMed
26.↵
1. Sener RN
. Diffusion MRI: apparent diffusion coefficient (ADC) values in the normal brain and a classification of brain disorders based on ADC values. Comput Med Imaging Graph 2001;25:299–326 doi:10.1016/s0895-6111(00)00083-5 pmid:11356324
CrossRef PubMed
27.↵
1. Filippi M,
2. Campi A,
3. Dousset V, et al
. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995;45:478–82 doi:10.1212/wnl.45.3.478 pmid:7898700
Abstract/FREE Full Text
28.↵
1. Ciccarelli O,
2. Werring DJ,
3. Wheeler-Kingshott CA, et al
. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 2001;56:926–33 doi:10.1212/wnl.56.7.926 pmid:11294931
Abstract/FREE Full Text
29.↵
1. Jardim L,
2. Vedolin L,
3. Schwartz IV, et al
. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 2004;27:229–40 doi:10.1023/B:BOLI.0000028794.04349.91 pmid:15159654
CrossRef PubMed
30.↵
1. Fellgiebel A,
2. Gartenschläger M,
3. Wildberger K, et al
. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis 2014;38:448–56 doi:10.1159/000369293 pmid:25502511
CrossRef PubMed

Received May 3, 2023.
Accepted after revision August 16, 2023.

In this issue

Download PDF

Email Article

Citation Tools

Purchase

Cited By...

More in this TOC Section

Show more ADULT BRAIN

[1] 1.↵
Fabry H
. Angiokeratoma corporis diffusum: Fabry disease—historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr 2002;91:3–5 doi:10.1111/j.1651-2227.2002.tb03102.x pmid:12572835
CrossRef PubMed

[2] Fabry H

[3] 2.↵
Zarate YA,
Hopkin RJ
. Fabry’s disease. Lancet 2008;372:1427–35 doi:10.1016/S0140-6736(08)61589-5 pmid:18940466
CrossRef PubMed

[4] Zarate YA,

[5] Hopkin RJ

[6] 3.↵
Jardim LB,
Aesse F,
Vedolin LM, et al
. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr .2006;64:711–17 doi:10.1590/s0004-282x2006000500002
CrossRef PubMed

[7] Jardim LB,

[8] Aesse F,

[9] Vedolin LM, et al

[10] 4.↵
Körver S,
Vergouwe M,
Hollak CEM, et al
. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Mol Genet Metab 2018;125:205–16 doi:10.1016/j.ymgme.2018.08.014
CrossRef PubMed

[11] Körver S,

[12] Vergouwe M,

[13] Hollak CEM, et al

[14] 5.↵
Ulivi L,
Kanber B,
Prados F, et al
. White matter integrity correlates with cognition and disease severity in Fabry disease. Brain 2020;143:3331–42 doi:10.1093/brain/awaa282 pmid:33141169
CrossRef PubMed

[15] Ulivi L,

[16] Kanber B,

[17] Prados F, et al

[18] 6.↵
Murphy P,
Williams F,
Davagnanam I, et al
. Cognitive dysfunction and white matter hyperintensities in Fabry disease. J Inherit Metab Dis 2022;45:782–95 doi:10.1002/jimd.12472 pmid:34994980
CrossRef PubMed

[19] Murphy P,

[20] Williams F,

[21] Davagnanam I, et al

[22] 7.↵
Rost NS,
Cloonan L,
Kanakis AS, et al
. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology 2016;86:1880–86 doi:10.1212/WNL.0000000000002673 pmid:27164662
Abstract/FREE Full Text

[23] Rost NS,

[24] Cloonan L,

[25] Kanakis AS, et al

[26] 8.↵
Arends M,
Wanner C,
Hughes D, et al
. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 2017;28:1631–41 doi:10.1681/ASN.2016090964 pmid:27979989
Abstract/FREE Full Text

[27] Arends M,

[28] Wanner C,

[29] Hughes D, et al

[30] 9.↵
Fellgiebel A,
Keller I,
Marin D, et al
. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009;72:63–68 doi:10.1212/01.wnl.0000338566.54190.8a pmid:19122032
Abstract/FREE Full Text

[31] Fellgiebel A,

[32] Keller I,

[33] Marin D, et al

[34] 10.↵
Rombach SM,
Twickler TB,
Aerts JM, et al
. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 2010;99:99–108 doi:10.1016/j.ymgme.2009.10.004 pmid:19900828
CrossRef PubMed

[35] Rombach SM,

[36] Twickler TB,

[37] Aerts JM, et al

[38] 11.↵
Wei EP,
Kontos HA,
Beckman JS
. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol 1996;271(3 Pt 2):H1262–66 doi:10.1152/ajpheart.1996.271.3.H1262 pmid:8853367
CrossRef PubMed

[39] Wei EP,

[40] Kontos HA,

[41] Beckman JS

[42] 12.↵
Moore DF,
Kaneski CR,
Askari H, et al
. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258–63 doi:10.1016/j.jns.2007.01.053 pmid:17362993
CrossRef PubMed

[43] Moore DF,

[44] Kaneski CR,

[45] Askari H, et al

[46] 13.↵
Moore DF,
Altarescu G,
Barker WC, et al
. White matter lesions in Fabry disease occur in “prior” selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003;62:231–40 doi:10.1016/j.brainresbull.2003.09.021 pmid:14698356
CrossRef PubMed

[47] Moore DF,

[48] Altarescu G,

[49] Barker WC, et al

[50] 14.↵
Böttcher T,
Rolfs A,
Tanislav C, et al
. Fabry disease: underestimated in the differential diagnosis of multiple sclerosis? PLoS One 2013;8:e71894 doi:10.1371/journal.pone.0071894 pmid:24015197
CrossRef PubMed

[51] Böttcher T,

[52] Rolfs A,

[53] Tanislav C, et al

[54] 15.↵
Albrecht J,
Dellani PR,
Müller MJ, et al
. Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 2007;78:964–69 doi:10.1136/jnnp.2006.112987 pmid:17449543
Abstract/FREE Full Text

[55] Albrecht J,

[56] Dellani PR,

[57] Müller MJ, et al

[58] 16.↵
Paavilainen T,
Lepomäki V,
Saunavaara J, et al
. Diffusion tensor imaging and brain volumetry in Fabry disease patients. Neuroradiology 2013;55:551–58 doi:10.1007/s00234-012-1131-8 pmid:23292181
CrossRef PubMed

[59] Paavilainen T,

[60] Lepomäki V,

[61] Saunavaara J, et al

[62] 17.↵
Körver S,
Longo MG,
Lima MR, et al
. Determinants of cerebral radiological progression in Fabry disease. J Neurol Neurosurg Psychiatry 2020;91:756–63 doi:10.1136/jnnp-2019-322268 pmid:32317398
Abstract/FREE Full Text

[63] Körver S,

[64] Longo MG,

[65] Lima MR, et al

[66] 18.↵
Tol van der L,
Cassiman D,
Houge G, et al
. Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep 2014;17:83–90 doi:10.1007/8904_2014_342 pmid:25224312
CrossRef PubMed

[67] Tol van der L,

[68] Cassiman D,

[69] Houge G, et al

[70] 19.↵
Smid BE,
Van Der Tol L,
Cecchi F, et al
. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol 2014;177:400–08 doi:10.1016/j.ijcard.2014.09.001 pmid:25442977
CrossRef PubMed

[71] Smid BE,

[72] Van Der Tol L,

[73] Cecchi F, et al

[74] 20.↵
Schmidt P
. Bayesian Inference for Structured Additive Regression Models for Large-Scale Problems with Applications to Medical Imaging. Mathematics January 17, 2017. https://www.semanticscholar.org/paper/Bayesian-inference-for-structured-additive-models-Schmidt/edc315de56ff336b75f36b30bad74fab231d39ca. Accessed June 20, 2022

[75] Schmidt P

[76] 21.↵
Bates D,
Mächler M,
Bolker BM, et al
. Fitting linear mixed-effects models using lme4. Journal of Statistical Software 2015;67 doi:10.18637/jss.v067.i01
CrossRef PubMed

[77] Bates D,

[78] Mächler M,

[79] Bolker BM, et al

[80] 22.↵
Baayen RH,
Davidson DJ,
Bates DM
. Mixed-effects modeling with crossed random effects for subjects and items. Journal of Memory and Language 2008;59:390–412 doi:10.1016/j.jml.2007.12.005
CrossRef PubMed

[81] Baayen RH,

[82] Davidson DJ,

[83] Bates DM

[84] 23.↵
Fellgiebel A,
Müller MJ,
Mazanek M, et al
. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005;65:600–02 doi:10.1212/01.wnl.0000173030.70057.eb pmid:16116124
Abstract/FREE Full Text

[85] Fellgiebel A,

[86] Müller MJ,

[87] Mazanek M, et al

[88] 24.↵
Fellgiebel A,
Mazanek M,
Whybra C, et al
. Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. J Neurol 2006;253:780–87 doi:10.1007/s00415-006-0118-y pmid:16511647
CrossRef PubMed

[89] Fellgiebel A,

[90] Mazanek M,

[91] Whybra C, et al

[92] 25.↵
Burzynska AZ,
Preuschhof C,
Bäckman L, et al
. Age-related differences in white matter microstructure: region-specific patterns of diffusivity. Neuroimage 2010;49:2104–12 doi:10.1016/j.neuroimage.2009.09.041 pmid:19782758
CrossRef PubMed

[93] Burzynska AZ,

[94] Preuschhof C,

[95] Bäckman L, et al

[96] 26.↵
Sener RN
. Diffusion MRI: apparent diffusion coefficient (ADC) values in the normal brain and a classification of brain disorders based on ADC values. Comput Med Imaging Graph 2001;25:299–326 doi:10.1016/s0895-6111(00)00083-5 pmid:11356324
CrossRef PubMed

[97] Sener RN

[98] 27.↵
Filippi M,
Campi A,
Dousset V, et al
. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995;45:478–82 doi:10.1212/wnl.45.3.478 pmid:7898700
Abstract/FREE Full Text

[99] Filippi M,

[100] Campi A,

[101] Dousset V, et al

[102] 28.↵
Ciccarelli O,
Werring DJ,
Wheeler-Kingshott CA, et al
. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 2001;56:926–33 doi:10.1212/wnl.56.7.926 pmid:11294931
Abstract/FREE Full Text

[103] Ciccarelli O,

[104] Werring DJ,

[105] Wheeler-Kingshott CA, et al

[106] 29.↵
Jardim L,
Vedolin L,
Schwartz IV, et al
. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 2004;27:229–40 doi:10.1023/B:BOLI.0000028794.04349.91 pmid:15159654
CrossRef PubMed

[107] Jardim L,

[108] Vedolin L,

[109] Schwartz IV, et al

[110] 30.↵
Fellgiebel A,
Gartenschläger M,
Wildberger K, et al
. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis 2014;38:448–56 doi:10.1159/000369293 pmid:25502511
CrossRef PubMed

[111] Fellgiebel A,

[112] Gartenschläger M,

[113] Wildberger K, et al

Main menu

User menu

Search

American Journal of Neuroradiology

Progressive Changes in Cerebral Apparent Diffusion Values in Fabry Disease: A 5-Year Follow-up MRI Study

Abstract

ABBREVIATIONS: